Table 1 Clinico-pathological and molecular features of 1915 patients who were included in our analyses and underwent surgery between 1998 and 2010 (column A), highlighting the features of 6 patients with MC occurring during the first 10Â years of follow up and considered in the analyses (column B)
Collected parameters | Column A | Column B |
|---|---|---|
Patients n = 1915 (%) | Patients with MC n = 6 (%) | |
Age at diagnosis of BC | ||
 - <50 years | 338 (17.6 %) | 6 (100 %) |
 - ≥50 years | 1577 (82.4 %) | 0 |
Treatment | ||
 - T (umorectomy) | 1400 (73.1 %) | 2 (33.3 %) |
 - M (astectomy) | 515 (26.9 %) | 4 (66.7 %) |
Histological type | ||
 - IDC | 1154 (60.3 %) | 5 (83.3 %) |
 - ILI | 348 (18.2 %) | 0 |
 - Mixed IDC-ILI | 146 (7.6 %) | 1 (16.7 %) |
 - Others | 267 (13.9 %) | 0 |
Histological grade | ||
 - G1 | 564 (29.5 %) | 0 |
 - G2 | 908 (47.4 %) | 2 (33.3 %) |
 - G3 | 435 (22.7 %) | 4 (66.7 %) |
 - Not available | 8 (0.4 %) | 0 |
Tumor size | ||
 - ≤ 15 mm | 1019 (53.2 %) | 0 |
 - > 15 mm | 890 (46.5 %) | 6 (100 %) |
 - Not available | 6 (0.3 %) | 0 |
Vascular invasion | ||
 - No | 1271 (66.4 %) | 1 (16.7 %) |
 - Yes | 626 (32.7 %) | 5 (83.3 %) |
 - Not available | 18 (0.9 %) | 0 |
pT stage | ||
 - pT1 | 1342 (70.1 %) | 1 (16.7 %) |
 - pT2 | 493 (25.7 %) | 5 (83.3 %) |
 - pT3-4 | 76 (4 %) | 0 |
 - Not available | 4 (0.2 %) | 0 |
pN stage | ||
 - Negative (including ITC/micrometastasis)/pN0 | 1335 (69.7 %) | 1 (16.7 %) |
 - from 1 to 3 nodes positive/pN1 | 338 (17.7 %) | 2 (33.3 %) |
 - >3 nodes positive/pN2-pN3 | 167 (8.7 %) | 3 (50 %) |
 - Not available | 75 (3.9 %) | 0 |
cM stage at diagnosis | ||
 cM0 | 1889 (98.6 %) | 4 (66.7 %) |
 cM1 | 26 (1.4 %) | 2 (33.3 %) |
Bone metastases | ||
 - no | 1818 (94.9 %) | 3 (50 %) |
 - yes | 97 (5.1 %) | 3 (50 %) |
Brain metastases | ||
 - no | 1898 (99.1 %) | 1 (16.7 %) |
 - yes | 17 (0.9 %) | 5 (83.3 %) |
Metastases in other site, NAS | ||
 - no | 1686 (88 %) | 0 |
 - yes | 229 (12 %) | 6 (100 %) |
ER status | ||
 Negative | 190 (9.9 %) | 3 (50 %) |
 Positive | 1693 (88.4 %) | 3 (50 %) |
 Not available | 32 (1.7 %) | 0 |
PR status | ||
 - Negative | 256 (13.4 %) | 2 (33.3 %) |
 - Positive | 1365 (71.3 %) | 3 (50 %) |
 - Not available | 294 (15.4 %) | 1 (16.7 %) |
Ki67 | ||
 - <20 % | 1103 (57.6 %) | 2 (33.3 %) |
 - ≥20 % | 741 (38.7 %) | 4 (66.7 %) |
 - Not available | 71 (3.7 %) | 0 |
HER2 | ||
 - negative | 1662 (86.8 %) | 3 (50 %) |
 - positive | 151 (7.9 %) | 3 (50 %) |
 - Not available | 101 (5.3 %) | 0 |
Neoadjuvant chemotherapy | ||
 - No | 1836 (95.9 %) | 3 (50 %) |
 - Yes | 79 (4.1 %) | 3 (50 %) |
Adjuvant treatment | ||
 - Chemotherapy | 722 (37.7 %) | 4 (66.7 %) |
 - Radiotherapy | 1352 (70.6 %) | 1 (16.7 %) |
 - Hormone therapy | 1520 (79.4 %) | 2 (33.3 %) |